U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07766187) titled 'Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma' on July 20.
Brief Summary: The purpose of this research is to evaluate whether adding histotripsy to maintenance durvalumab increases immune response and to assess the safety of this combination for participants with advanced intrahepatic cholangiocarcinoma (iCCA). Histotripsy is a non-invasive, non-thermal treatment that uses focused ultrasound energy to destroy tumor tissue. 12 people will be enrolled in this study.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Intrahepatic Cholangiocarcinoma
Interventio...